Divis Laboratories Limited is among India’s leading pharmaceutical companies. The firm is headquartered in Hyderabad, Andhra Pradesh. Divis Laboratories is primarily known for the production of active pharmaceutical ingredients (APIs) and intermediates. APIs are the key components in the manufacture of pharmaceutical products. Divis Laboratories had a humble beginning with a single research centre in Hyderabad. The company began its journey when scientist and entrepreneur Dr. Murali K. Divi founded Divi’s Research Center (DRC) in 1990. 1994 was the year when Divi’s Research Center rebranded and changed the company name to Divis Laboratories to mark its entry into the API manufacturing business. Divis Laboratories opened its first manufacturing facility near Hyderabad in 1995 and began production of APIs. 2002 was the year when operations were initiated at Divis Laboratories’ second manufacturing unit in Vishakhapatnam, Andhra Pradesh. In 2003, Divis Laboratories launched its Initial Public Offer (IPO). 2007 was the year when Divis Laboratories ventured into Nutraceuticals business as it opened the doors of a new Nutraceuticals facility at its Vizag unit. A new research centre was inaugurated by Divis Laboratories in Hyderabad in 2010. Five years later, Divis Laboratories inaugurated a new corporate office in Hyderabad. 2018 was an important year for Divis Laboratories when it greatly expanded its product portfolio to over 30 products. Divis Laboratories made a $250 million investment in 2019. The purpose behind the investment was to expand production in both its units. Divis Laboratories set up another manufacturing plant in Kakinada, Andhra Pradesh in 2021. As of March 2022, Divis Laboratories has a headcount of over 16,500 trained professionals across departments and over 400 scientists. The company’s products are sold in over 100 countries across the globe.
Products and services
Divis Laboratories is in the business of custom synthesis of Active Pharmaceutical Ingredients (APIs) and intermediates. The company also makes nutraceuticals. The company owns and operates two manufacturing units in Hyderabad and Vizag respectively. The company’s manufacturing units have been inspected by global regulatory agencies, such as the US FDA, European Medicines Agency (EMA) and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). The company manufactures APIs for therapeutic uses like anti-inflammatory and anti-hypertensive. Apart from production, Divis Laboratories also has a strong focus on research and development in order to develop new APIs and processes.
Shares of Divis Laboratories are listed on BSE, NSE and MCX Stock Exchange. The company is a part of multiple indices like Nifty 50, Nifty 500, S&P BSE Sensex 50 etc.
DATA SOURCES: Corporate data, historical price & volume data published on this website have been sourced from CMOTS Internet Technologies Pvt. Ltd. BSE Quotes and NSE Quotes have been sourced from BSE Limited and NSE Data & Analytics Limited, respectively. All timestamps reflected here are in IST (Indian Standard Time). Stock Analysis section has been sourced from the mentioned partners.
DISCLAIMER: Any and all content on this website, including the tools/ analysis, is provided to you only for convenience and on an “as-is, as-available” basis without representation and warranties of any kind. The content and any output of such tools/ analysis is for informational purposes only and should not be relied upon or construed as investment advice or guarantee for any specific performance/ returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.
Copyright©2023 Living Media India Limited. For reprint rights: Syndications Today